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Background: Myeloablative conditioning and AlloSCT in
childrenwith AML in CR1 is associated with a 60% event-free
survival (EFS) but may be associated with signiﬁcant acute
toxicity and late effects (Woods et al; Blood, 2001). Reduced-
intensity conditioning (RIC) and AlloSCT in children is safe,
feasible and may be associated with less adverse effects (Del
Toro/Cairo et al, BMT, 2004; Satwani/Cairo, BBMT, 2013).
Gemtuzumab ozogamicin (GO) has been demonstrated to
induce response in 30% CD33+ pediatric relapsed/refractory
AML (Sievers et al, JCO, 2001). The dose of GO is signiﬁcantly
lower when combined with chemotherapy (Aplenc, JCO,
2008).Objective: We examined the feasibility and toxicity of RIC-
AlloSCT followed by GO targeted immunotherapy in children
with CD33+ AML in CR1/CR2.
Methods: Conditioning consisted of ﬂudarabine 30mg/m2 x
6 days and busulfan 3.2-4mg/kg x 2 days  rabbit ATG 2mg/
kg x 4 days followed by AlloSCT from matched related/un-
related donors. GO was administered 55 days post-AlloSCT
in 2 doses (8 weeks apart), following a dose escalation design
(4.5, 6, 7.5 and 9 mg/m2).
Results: Thirteen patients with average risk AML received
RIC AlloSCT: median age of 14.5 years at transplant (range:
11-21); M:F:7:6; disease status at AlloSCT: 10 CR1, 3 CR2.
Eleven patients received AlloSCT from 5-6/6 HLA matched
family donors: 8 received PBSCs, 2 received BM and 1
received umbilical cord blood transplantation (UCBT). Two
patients received an unrelated graft (HLA matching 14/6 and
1 9/10) from UCBT and BM, respectively. Neutrophil
engraftment and platelet engraftment was observed in 13
patients (100%) and was achieved at a median of 14 days
(range 7-31) and 18 days (range 10-52), respectively. Three
patients received GO at dose level 1 (4.5 mg/m2/dose), 5 at
dose level 2 (6 mg/m2/dose), 3 at dose level 3 (7.5 mg/m2/
dose) and 2 at dose level 4 (9 mg/m2/dose). The ﬁrst dose of
GO was administered after 55 days post-transplant. One
patient experienced grade III transaminitis which resolved;
no grade IV transaminitis, no grade III/IV hyperbilirubinemia
or VOD. Twelve and 7 patients experienced grade 4 myeloid
toxicity and grade 4 thrombocytopenia, respectively.
Following the ﬁrst dose of GO, neutrophil and platelet re-
covery was achieved at median of 14 days (range 9-18) and
11 days (range 6-17), respectively. The second dose of GOwas
given at a median of 143 days (range: 120-209) post-trans-
plant. The probability of grade II-IV aGVHD was 15.4%.
Probability of overall survival following RIC-AlloSCT and GO
consolidation at 1 and 3 years was 83.3% and 65.6%,
respectively. There have been no DLTs observed in this cohort
during this time period.
Conclusion: This preliminary data demonstrates that RIC
followed by AlloSCT and consolidationwith GO appears to be
safe in children with CD33+ AML in CR1/CR2. A larger cohort
with longer follow-up is required to determine the long-term
clinical signiﬁcance.
